1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine

BACKGROUND: Bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) is a guidelines-recommended single-tablet regimen (STR) for people living with HIV-1 (PLWH). Week (W) 48 primary endpoint results of this phase 3 study switching to B/F/TAF from dolutegravir (DTG), abacavir (ABC) and lamivudi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brar, Indira, Ruane, Peter, Ward, Douglas, Molina, Jean-michel, Mills, Anthony, Berhe, Mezgebe, Brinson, Cynthia, Rampogal, Moti, Benson, Paul, Henry, Keith, Huang, Hailin, Andreatta, Kristen, Martin, Hal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777514/
http://dx.doi.org/10.1093/ofid/ofaa439.1214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777514/
http://dx.doi.org/10.1093/ofid/ofaa439.1214

Ejemplares similares